STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Stoke Therapeutics in a report released on Thursday, June 12th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($0.34) per share for the year, down from their prior estimate of $0.03. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics' FY2026 earnings at ($3.36) EPS.

A number of other research analysts have also recently commented on STOK. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $11.53 on Monday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $16.62. The stock's 50 day simple moving average is $9.30 and its two-hundred day simple moving average is $9.63. The stock has a market cap of $629.50 million, a price-to-earnings ratio of -5.49 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently bought and sold shares of the company. RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after buying an additional 471,240 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in Stoke Therapeutics by 6.1% in the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock worth $51,111,000 after acquiring an additional 265,395 shares during the last quarter. Toronto Dominion Bank bought a new position in Stoke Therapeutics in the 4th quarter valued at approximately $35,001,000. Vanguard Group Inc. boosted its stake in Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company's stock valued at $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Finally, Siren L.L.C. increased its holdings in shares of Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after purchasing an additional 247,347 shares in the last quarter.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,748 shares of company stock worth $225,687 in the last 90 days. Insiders own 9.50% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.